
    preliminary terminated due to inefficacy
  
['melanoma']
['metformin', 'melatonin', 'dacarbazine']

        Inclusion Criteria:

          -  Age >18.

          -  Obtained Inform Consent

          -  Morphologically confirmed disseminated Stage IV melanoma

          -  Eastern Collaborative Oncology Group Performance Status Scale 0 - 2.

          -  Expected survival >3 month

        Exclusion Criteria:

          -  Evidence of active brain lesions (brain lesions after stereotaxic ray therapy allowed)

          -  Evidence of liver and bone marrow clinically meaningful disfunction

          -  Severe uncontrolled concomitant conditions and diseases

          -  Pregnancy or lactation

          -  Systemic therapy for disseminated melanoma

          -  Second malignancy

          -  Diabetes mellitus requiring drug therapy

          -  Any condition preventing study participation by investigator opinion
      